Navigation Links
Rising Incidence of Stroke Drives the Global Intracranial Stents Market, According to New Report by Global Industry Analysts, Inc.
Date:8/29/2013

San Jose, California (PRWEB) August 29, 2013

Follow us on LinkedIn – Stroke is one of the leading causes of morbidity and mortality in the world. Aging population constitutes a major growth engine for the global intracranial stents market, given that people above the age of 40 years are at a higher risk of developing cerebrovascular diseases. The fast aging societies in advanced economies of North America, Western Europe and Japan coupled with the huge aging demography in highly populous developing economies such as China and India, are expected to result in a considerable increase in health conditions warranting a rise in demand for intracranial stenting procedures. Additionally, changing lifestyles, increasing stress levels, hypertension, rising obesity rates, increasing blood cholesterol and blood pressure levels, smoking and hyperlipidemia, among others are some of the major factors that have increased the incidence rates of stroke. The rising number of cases of restenosis, indicated by the recurrence of stenosis and subsequent constriction in blood flow in previously treated arteries, is fuelling the requirement for intracranial stenting procedures.

Conventional therapy involves the prescription of aspirin, Warfarin and other blood thinning agents for restoring normal blood flow in patients with narrowed arteries. Intracranial Stents, inspired by the coronary and cardiovascular stent systems, have revolutionized treatment of arterial blockages and clot retrieval in patients suffering with cerebral aneurysms, severe intracranial atherosclerotic disease (ICAD), intracranial stenosis, acute ischemic stroke and other diseases of the brain. These stenting systems have been successfully used in
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
2. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
3. Healthcare Sales Jobs Rising Despite Challenges Facing the Industry
4. Blood Glucose Testing and Diabetes Management - Dramatic Increase in the Incidence of Diabetes
5. Black Women Have Higher Incidence of Multiple Sclerosis than White Women
6. Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
7. Powerful AAC Device With Intel® i7 Processor Enables Natural Communication for Stroke, ALS and Autism Patients
8. Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries
9. Latest Advances in Treatment for Alzheimers, Traumatic Brain Injury and Stroke to Be Presented at Symposium
10. St. Josephs Hospital is the First in Florida to Offer Non-invasive Test to Predict Stroke Risk
11. National Stroke Association Teams With Clinical Trial Matching Service CureLauncher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Leading CEOs, CSOs, CMOs, and ... space join prominent academics and key investors for Neuro Advance Boston, October 14, ... Boston. , Neuro Advance Boston focuses on the latest developments and opportunities ...
(Date:9/1/2015)... MA (PRWEB) , ... September 01, 2015 , ... ... its new Director of Business Development, Asia Pacific. In this newly-created position, Gibbs ... the awareness and use of iLab’s suite of tools. This entails not only ...
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, a leading ... new version of its flagship DNA design platform, which has been enhanced to ... into numerous genetic parts, which in turn can be recombined using specific sets ...
(Date:8/31/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... air emission abatement projects in North America ... for a municipality in the Southern USA ... that failed to meet the customer,s requirements. This demonstrates the value ... S. Webb , President and Chief Executive Officer.  ...
Breaking Biology Technology:Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
Biology Products: